| Title |
LOX-1 in atherosclerosis: biological functions and pharmacological modifiers
|
|---|---|
| Published in |
Cellular and Molecular Life Sciences, November 2012
|
| DOI | 10.1007/s00018-012-1194-z |
| Pubmed ID | |
| Authors |
Suowen Xu, Sayoko Ogura, Jiawei Chen, Peter J. Little, Joel Moss, Peiqing Liu |
| Abstract |
Lectin-like oxidized LDL (oxLDL) receptor-1 (LOX-1, also known as OLR-1), is a class E scavenger receptor that mediates the uptake of oxLDL by vascular cells. LOX-1 is involved in endothelial dysfunction, monocyte adhesion, the proliferation, migration, and apoptosis of smooth muscle cells, foam cell formation, platelet activation, as well as plaque instability; all of these events are critical in the pathogenesis of atherosclerosis. These LOX-1-dependent biological processes contribute to plaque instability and the ultimate clinical sequelae of plaque rupture and life-threatening tissue ischemia. Administration of anti-LOX-1 antibodies inhibits atherosclerosis by decreasing these cellular events. Over the past decade, multiple drugs including naturally occurring antioxidants, statins, antiinflammatory agents, antihypertensive and antihyperglycemic drugs have been demonstrated to inhibit vascular LOX-1 expression and activity. Therefore, LOX-1 represents an attractive therapeutic target for the treatment of human atherosclerotic diseases. This review aims to integrate the current understanding of LOX-1 signaling, regulation of LOX-1 by vasculoprotective drugs, and the importance of LOX-1 in the pathogenesis of atherosclerosis. |
Mendeley readers
The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 141 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 27 | 19% |
| Student > Ph. D. Student | 21 | 15% |
| Student > Master | 19 | 13% |
| Researcher | 13 | 9% |
| Student > Postgraduate | 9 | 6% |
| Other | 22 | 15% |
| Unknown | 31 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 21% |
| Biochemistry, Genetics and Molecular Biology | 29 | 20% |
| Agricultural and Biological Sciences | 18 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 8% |
| Nursing and Health Professions | 7 | 5% |
| Other | 12 | 8% |
| Unknown | 35 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2022.
All research outputs
#5,611,796
of 26,017,215 outputs
Outputs from Cellular and Molecular Life Sciences
#1,243
of 5,993 outputs
Outputs of similar age
#41,287
of 204,854 outputs
Outputs of similar age from Cellular and Molecular Life Sciences
#6
of 29 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,993 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,854 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.